Skip to content

Advertisement

  • Poster presentation
  • Open Access

The core outcome measures in effectiveness trials (COMET) initiative: five years on

  • Paula Williamson1,
  • Douglas Altman2,
  • Jane Blazeby3,
  • Michael Clarke4,
  • Elizabeth Gargon1,
  • Sarah Gorst1 and
  • Sean Tunis5
Trials201516(Suppl 2):P69

https://doi.org/10.1186/1745-6215-16-S2-P69

Published: 16 November 2015

Keywords

Public InvolvementPatient OrganisationEffectiveness TrialInternational AdvisoryGuideline Developer

Core outcome sets (COS) can reduce waste in research, through measurement of an agreed set of outcomes across all trials in a particular area of health. The COMET Initiative was launched in 2010 to (i) raise awareness of problems with outcomes in trials; (ii) encourage COS development and uptake; (iii) promote patient and public involvement in COS development; (iv) provide resources to facilitate this; and (v) encourage evidence-based COS development.

This talk will review progress and challenges over our first five years. It will describe our work with multiple stakeholders to facilitate engagement, including funders, trialists, patient organisations, systematic reviewers, editors, industry, regulators, and guideline developers. The perception that COMET was a ‘UK thing’ has been dispelled, with the establishment of an International Advisory Group and meetings in Rome (2014) and Calgary (2015).

Highlights include the development of a searchable repository of COS studies, and completion of the first comprehensive systematic review of published COS (recently updated to December 2014). Over 7800 searches have been done of the online repository, most visitors in 2014 were from outside the UK and we will present findings from a pop-up survey of why people search it.

Promoting broader uptake of COS by researchers and securing funding for initiatives aimed at reducing waste in research remain major challenges. As awareness of the need for COS continues to grow and knowledge of the COMET Initiative increases, this is an appropriate moment to present our future proposals, including a research agenda, to the trials methodology community.

Authors’ Affiliations

(1)
University of Liverpool, Liverpool, UK
(2)
University of Oxford, Oxford, UK
(3)
University of Bristol, Bristol, UK
(4)
Queen's University Belfast, Belfast, UK
(5)
Center for Medical Technology and Policy, Baltimore, USA

Copyright

© Williamson et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.

Advertisement